3 active not recruiting. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Active not recruiting 3 |
Follow Hypopigmentation: new trials by email Literature Review of Hypopigmentation trials Research Report on Hypopigmentation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo Ritlecitinib, Ritlecitinib 100 mg, Placebo - Vitiligo | Phase 3 | Active not recruiting | Pfizer | 394 | 2024-01-19 | 2026-09-28 |
| A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo Upadacitinib, Placebo, NB-UVB (narrow-band ultraviolet B) Phototherapy - Vitiligo | Phase 3 | Active not recruiting | AbbVie | 614 | 2023-12-19 | 2026-06-09 |
| A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo Afamelanotide and NB-UVB Light, NB-UVB Light - Vitiligo | Phase 3 | Active not recruiting | Clinuvel, Inc. | 200 | 2023-10-11 | 2025-07-08 |
Vitiligo (3)
Pigmentation Disorders (3) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3)
Phototherapy (1) · afamelanotide (1) · upadacitinib (1)
AbbVie (1) · Clinuvel, Inc. (1) · Pfizer (1)
United States (3) · Bulgaria (2) · Canada (2) · China (2) · France (2) · Germany (2) · Japan (2) · Poland (2) · South Korea (2) · Spain (2) · United Kingdom (2) · Argentina (1) · Australia (1) · Belgium (1) · Hungary (1)
2023 (2)